quinta-feira, julho 06, 2006
TMC114 e resistências
Everything you wanted to know (almost) about resistance to darunavir; discussion of cross-resistance and comparisons with tipranavir
Written By Mark Mascolini
Darunavir, tagged TMC114 as it sailed through clinical trials, got its FDA seal of approval shortly after the Resistance Workshop, where researchers offered a workshop-leading six studies on the Tibotec protease inhibitor (PI). That left a little room to discuss another recently licensed PI, tipranavir, and one still in the pipeline, brecanavir. But while brecanavir perks along, clinicians and people with PI failures on their charts want to know if darunavir or tipranavir will work better for them. This article will attempt at least the first steps toward an answer.